Anna Lisa Ridolfo

ORCID: 0000-0003-1106-6219
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • SARS-CoV-2 and COVID-19 Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Hepatitis C virus research
  • Long-Term Effects of COVID-19
  • COVID-19 and healthcare impacts
  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Malaria Research and Control
  • Research on Leishmaniasis Studies
  • Trypanosoma species research and implications
  • Viral-associated cancers and disorders
  • Mosquito-borne diseases and control
  • Parasites and Host Interactions
  • Bacterial Identification and Susceptibility Testing
  • Hepatitis B Virus Studies
  • Cytomegalovirus and herpesvirus research
  • Lymphoma Diagnosis and Treatment
  • Antibiotic Use and Resistance
  • Nail Diseases and Treatments
  • Travel-related health issues

Luigi Sacco Hospital
2016-2025

ASST Fatebenefratelli Sacco
2016-2025

University of Milan
2012-2023

University of Colorado Anschutz Medical Campus
2022

Jagiellonian University
2022

University of Colorado Denver
2022

Ospedale San Paolo
2018-2019

Mylan (Switzerland)
2006

Hospital for Tropical Diseases
2000-2004

National Research Council
1991-2002

Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19.In this open-label prospective study we describe clinical characteristics and outcome 51 hospitalized confirmed COVID-19 pneumonia treated tocilizumab intravenously. All had elevated plasma level (>40 pg/mL) oxygen saturation <93% ambient air. Clinical outcomes, support, laboratory...

10.1016/j.ejim.2020.05.011 article EN other-oa European Journal of Internal Medicine 2020-05-21

Objectives: To investigate the prevalence, metabolic features and risk factors of a particular pattern fat redistribution (FR), characterized by progressive enlargement breast abdominal girth associated with wasting lower limbs, observed in HIV-infected women treated combined antiretroviral (ARV) therapy. Design: Cross-sectional study. Setting: Outpatients attending Institute Infectious Diseases, University Milan, Italy. Patients methods: two or more ARV drugs, between December 1997 February...

10.1097/00002030-199903110-00004 article EN AIDS 1999-03-01

OBJECTIVES: We aimed to assess the frequency of ICU-acquired bloodstream infections in coronavirus disease 2019 patients. DESIGN: Retrospective observational study. SETTING: The emergency expansion an ICU from eight general beds 30 beds. PARTICIPANTS: Patients with admitted Luigi Sacco Hospital (Milan, Italy) for greater than or equal 48 hours between February 21, 2020, and April 30, 2020. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: per 1,000 days stay was calculated 89 patients,...

10.1097/ccm.0000000000004748 article EN Critical Care Medicine 2020-10-28

Adipose tissue alterations (ATA), which are common among persons treated with highly active antiretroviral therapy (HAART), can have substantial psychologic repercussions, a subsequent negative impact on the patient's quality of life and HAART adherence. However, cross-sectional nature studies precludes establishing direction causality relationship. The authors evaluated longitudinal relationship between ATA adherence to HAART. analysis included all participants in AdICoNA LipolCoNA...

10.1097/00126334-200212153-00011 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2002-12-01

Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of fractures osteonecrosis the femoral head is less understood. We investigated if exposure to ARVs increases both outcomes.EuroSIDA participants were followed assess osteonecrosis. Poisson regression identified clinical, laboratory demographic predictors either outcome. Ever, current, cumulative exposures assessed.During 86118 PYFU among 11820 included persons (median age 41y, 75% male, median baseline CD4...

10.1093/cid/cix167 article EN Clinical Infectious Diseases 2017-02-16

Background SARS-CoV-2 viremia has been found to be a potential prognostic factor in patients hospitalized for COVID-19. Objective We aimed assess the association between and mortality COVID-19 during different epidemic periods. Methods A prospective registry was queried extract all with an available performed at hospital admission March 2020 January 2022. assessed by means of GeneFinderTM Plus RealAmp Kit assay ELITe MGB ® using &lt;45 cycle threshold define positivity. Uni multivariable...

10.1371/journal.pone.0281052 article EN cc-by PLoS ONE 2023-04-28

Recent studies have highlighted the prognostic value of easily accessible inflammatory markers, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte (PLR) for predicting severe outcomes in patients affected by Coronavirus disease 2019 (COVID-19). Our study validates NLR PLR cut-off values from a prior cohort at IRCCS Policlinico San Matteo (OSM) Pavia, Italy, across two new cohorts different hospitals. This aims to enhance generalizability these indicators. In this retrospective...

10.1007/s40121-024-00967-6 article EN cc-by-nc Infectious Diseases and Therapy 2024-04-21

The current study describes the clinicopathologic characteristics of 36 patients with lung carcinoma and human immunodeficiency virus (HIV) infection observed within Italian Cooperative Group on AIDS Tumors (GICAT).Patients HIV collected by GICAT between 1986-1998 were evaluated retrospectively. As a control group, authors analyzed 102 age < 60 years but without who seen at CRO, National Cancer Institute, Aviano, Italy 1995-1996.Patients younger (38 vs. 53 years) previously smoked more...

10.1002/(sici)1097-0142(20000201)88:3<563::aid-cncr11>3.0.co;2-d article EN Cancer 2000-02-01

Objective: To measure the frequency and associated factors of cervicovaginal HIV shedding to determine impact sexually transmitted disease (STD) treatment on shedding. Design: Cross-sectional study with 1-week follow-up. Setting: Confidential clinic for female sex workers in Abidjan, Côte d'lvoire. Participants: A total 1201 workers. Interventions: STD based clinical signs. Main outcome measures: serostatus; at enrolment follow-up; status Results: Cervicovaginal HIV-1 HIV-1-seropositive...

10.1097/00002030-199710000-00001 article EN AIDS 1997-08-01

Background: Cross-sectional and retrospective surveys suggest that nucleoside reverse transcriptase inhibitors (NRTIs) contribute to the metabolic morphologic alterations observed in patients on antiretroviral therapy (ART). Objectives: To assess risk of developing body habitus changes (BHCs) abnormalities protease inhibitor (PI)-naive HIV-1-infected treated with two NRTIs, associated each these drugs. Design: Prospective cohort study. Patients Methods: The BHCs occurring 335 NRTIs were...

10.1097/00126334-200201010-00003 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2002-01-01

We retrospectively evaluated autopsy-proven invasive fungal infections (IFIs) in patients with AIDS who died between 1984 and 2002. IFIs were identified 297 (18.2%) of 1,630 autopsies. Their prevalence significantly decreased over time (from 25.0% 1984-1988 to 15% 1998-2002; P = .004), mainly owing a significant decrease pneumocystosis (P .017) cryptococcosis .003), whereas the aspergillosis histoplasmosis remained relatively stable candidiasis zygomycosis tended increase last years .028...

10.1309/ajcpraae8lz7dtne article EN American Journal of Clinical Pathology 2009-07-15

This paper describes how mortality among hospitalised COVID-19 patients changed during the first three waves of epidemic in Italy.This prospective cohort study used Kaplan-Meier method to analyse time-dependent probability death all admitted a referral centre Milan, Italy, consecutive periods of: 21 February-31 July 2020 (first wave, W1), 1 August 2020-31 January 2021 (second W2), and February-30 April (third W3). Cox models were examine association between period admission after adjusting...

10.1371/journal.pone.0263548 article EN cc-by PLoS ONE 2022-04-11

The incidence of thrombotic microangiopathy (TMA) was retrospectively evaluated in a cohort 1223 patients with acquired immunodeficiency syndrome (AIDS) who were observed from January 1985 through December 1996 (before the era highly active antiretroviral therapy [HAART]), and prospectively assessed for 347 AIDS during period 1997 2000 (during HAART era). Seventeen cases reported former (1.4%). increased risk developing TMA statistically significant cryptosporidiosis or AIDS-related cancer...

10.1086/344778 article EN Clinical Infectious Diseases 2002-12-15

The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients has increased over recent years. Most studies the risk and spectrum NADCs are primarily based on male populations, only a few have provided specific information regarding females.We retrospectively analyzed all incident occurring cohort followed up between 1985 2011. Incidence rates before after introduction highly active antiretroviral therapy (HAART) were examined using Poisson regression models. Standardized...

10.1097/qai.0b013e318282a189 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2012-12-31

The emergence of carbapenem-resistant Klebsiella pneumoniae strains is threatening antimicrobial treatment. Sixty-eight carbapenemase-producing K. isolated at Luigi Sacco University Hospital-ASST Fatebenefratelli (Milan, Italy) between 2012 and 2014 were characterised microbiologically molecularly. They tested for drug susceptibility carbapenemase phenotypes, investigated by means repetitive extra-genic palindromic polymerase chain reaction (REP-PCR), fully sequenced next-generation...

10.1186/s12879-017-2760-7 article EN cc-by BMC Infectious Diseases 2017-10-10
Annalisa Saracino P Lorenzini Sergio Lo Caputo Enrico Girardi Francesco Castelli and 95 more Paolo Bonfanti Stefano Rusconi Pietro Caramello N Abrescia Cristina Mussini Laura Monno Antonella d’Arminio Monforte M Moroni Massimo Andreoni Gioacchino Angarano Andrea Antinori Antonella d’Arminio Monforte Francesco Castelli Roberto Cauda Giovanni Di Perri Massimo Galli Rosaria Iardino Giuseppe Ippolito Adriano Lazzarin Carlo Federico Perno F von Schloesser Pierluigi Viale Antonella Castagna Francesca Ceccherini‐Silberstein Alessandro Cozzi‐Lepri Enrico Girardi Sergio Lo Caputo Cristina Mussini Massimo Puoti Adriana Ammassari Claudia Balotta Paolo Bonfanti Stefano Bonora Marco Borderi Maria Rosaria Capobianchi Antonella Cingolani Paola Cinque Andrea De Luca Antonio Di Biagio Nicola Gianotti Andrea Gori Giovanni Guaraldi Giuseppe Lapadula Miriam Lichtner Giordano Madeddu Franco Maggiolo Giulia Marchetti S Marcotullio Laura Monno Eugenia Quirós-Roldán Stefano Rusconi Annalisa Saracino Paola Cicconi Iuri Fanti Laura Galli P Lorenzini M. Shanyinda Alessandro Tavelli Andrea Giacometti Andrea Costantini S. Mazzoccato Carmen Rita Santoro Claudia Suardi Elisa Vanino Gabriella Verucchi C Minardi Tiziana Quirino C Abeli Paolo Emilio Manconi P Piano Jacopo Vecchiet Katia Falasca L Sighinolfi Daniela Segala Francesco Mazzotta Giovanni Cassola Claudio Viscoli A. Alessandrini R Piscopo Giovanni Mazzarello Claudio Maria Mastroianni Valeria Belvisi Ilaria Caramma Alessandro Chiodera Francesco Castelli Giuliano Rizzardini Anna Lisa Ridolfo R. Piolini Stefania Salpietro Laura Carenzi M C Moioli Camilla Tincati Cinzia Puzzolante N Abrescia Antonio Chirianni

10.1016/j.cmi.2015.10.026 article EN publisher-specific-oa Clinical Microbiology and Infection 2015-11-10

Background: Cross-sectional and retrospective surveys suggest that nucleoside reverse transcriptase inhibitors (NRTIs) contribute to the metabolic morphologic alterations observed in patients on antiretroviral therapy (ART). Objectives: To assess risk of developing body habitus changes (BHCs) abnormalities protease inhibitor (PI)-naive HIV-1-infected treated with two NRTIs, associated each these drugs. Design: Prospective cohort study. Patients Methods: The BHCs occurring 335 NRTIs were...

10.1097/00042560-200201010-00003 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2002-01-01
Coming Soon ...